Abstract
AbstractArtificial intelligence (AI) and Machine learning (ML) systems in medicine are poised to significantly improve health care, for example, by offering earlier diagnoses of diseases or recommending optimally individualized treatment plans. However, the emergence of AI/ML in medicine also creates challenges, which regulators must pay attention to. Which medical AI/ML-based products should be reviewed by regulators? What evidence should be required to permit marketing for AI/ML-based software as a medical device (SaMD)? How can we ensure the safety and effectiveness of AI/ML-based SaMD that may change over time as they are applied to new data? The U.S. Food and Drug Administration (FDA), for example, has recently proposed a discussion paper to address some of these issues. But it misses an important point: we argue that regulators like the FDA need to widen their scope from evaluating medical AI/ML-based products to assessing systems. This shift in perspective—from a product view to a system view—is central to maximizing the safety and efficacy of AI/ML in health care, but it also poses significant challenges for agencies like the FDA who are used to regulating products, not systems. We offer several suggestions for regulators to make this challenging but important transition.
Publisher
Springer Science and Business Media LLC
Subject
Health Information Management,Health Informatics,Computer Science Applications,Medicine (miscellaneous)
Reference20 articles.
1. IDx Technologies Inc. Autonomous AI that instantly detects disease. https://www.eyediagnosis.net (2018).
2. Abràmoff, M. D., Lavin, P. T., Birch, M., Shah, N. & Folk, J. C. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. npj Digit. Med. 1, 39 (2018).
3. FDA. Proposed regulatory framework for modifications to artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD). Discussion paper and request for feedback. https://www.fda.gov/media/122535/download (2019).
4. Babic, B., Gerke, S., Evgeniou, T. & Cohen, I. G. Algorithms on regulatory lockdown in medicine. Science 366, 1202–1204 (2019).
5. FDA. Computer-assisted surgical systems. https://www.fda.gov/medical-devices/surgery-devices/computer-assisted-surgical-systems#top (2019).
Cited by
117 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology;npj Precision Oncology;2024-01-30
2. FDA-Approved Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices: An Updated Landscape;Electronics;2024-01-24
3. Integrating ethics in AI development: a qualitative study;BMC Medical Ethics;2024-01-23
4. Developing, purchasing, implementing and monitoring AI tools in radiology: Practical considerations. A multi‐society statement from the ACR, CAR, ESR, RANZCR & RSNA;Journal of Medical Imaging and Radiation Oncology;2024-01-23
5. Developing, purchasing, implementing and monitoring AI tools in radiology: practical considerations. A multi-society statement from the ACR, CAR, ESR, RANZCR & RSNA;Insights into Imaging;2024-01-22